FHIR IG analytics| Package | hl7.fhir.uv.ebm |
| Resource Type | Composition |
| Id | Composition-236951.json |
| FHIR Version | R6 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: Composition 236951
version: 107; Last updated: 2025-10-07 17:12:54+0000; Language: en
Profile: SummaryOfFindings
url: https://fevir.net/resources/Composition/236951
identifier: FEvIR Object Identifier/236951, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-summary-of-findings-85394-85798
status: Final
type: Summary of Findings
date: 2025-10-07 17:12:54+0000
author: Qiukui Hao
title: SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
custodian: Computable Publishing LLC
relatesTo
type: Part Of
target: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)
relatesTo
type: Part Of
target: ComparativeEvidenceSynthesisReport: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-comparative-evidence-report-85394-85798)
relatesTo
type: Cite As
target:
SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236951. Revised 2025-10-07. Available at: https://fevir.net/resources/Composition/236951. Computable resource at: https://fevir.net/resources/Composition/236951#json.
FHIR
FHIRsmith{
"resourceType": "Composition",
"id": "236951",
"meta": {
"versionId": "107",
"lastUpdated": "2025-10-07T17:12:54.639Z",
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/summary-of-findings"
]
},
"language": "en",
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"url": "https://fevir.net/resources/Composition/236951",
"identifier": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "FEvIR Object Identifier"
},
"system": "https://fevir.net/FOI",
"value": "236951",
"assigner": {
"display": "Computable Publishing LLC"
}
},
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-summary-of-findings-85394-85798",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"status": "final",
"type": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "SummaryOfFindings",
"display": "SummaryOfFindings"
}
],
"text": "Summary of Findings"
},
"date": "2025-10-07T17:12:54.639Z",
"author": [
{
"display": "Qiukui Hao"
}
],
"title": "SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"custodian": {
"reference": "Organization/118079",
"type": "Organization",
"display": "Computable Publishing LLC"
},
"relatesTo": [
{
"type": "part-of",
"targetReference": {
"type": "Composition",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-conversion-report",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
}
},
{
"type": "part-of",
"targetReference": {
"type": "Composition",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-comparative-evidence-report-85394-85798",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "ComparativeEvidenceSynthesisReport: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
},
{
"type": "cite-as",
"targetMarkdown": "SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236951. Revised 2025-10-07. Available at: https://fevir.net/resources/Composition/236951. Computable resource at: https://fevir.net/resources/Composition/236951#json."
}
],
"section": [
{
"title": "Column Headers",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "column-headers",
"display": "Column Headers"
}
]
},
"section": [
{
"title": "Outcome Measure",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "outcome-measure",
"display": "Outcome Measure"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Outcome</p></div>"
}
},
{
"title": "Sample Size",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "sample-size",
"display": "Sample Size"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Sample Size</p></div>"
}
},
{
"title": "Result Without Treatment",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-comparator-alone",
"display": "Result with comparator alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Result Without Treatment</p></div>"
}
},
{
"title": "Result With Treatment--Observed",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone",
"display": "Result with intervention alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Result With Treatment (Observed)</p></div>"
}
},
{
"title": "Result With Treatment--Derived",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone-calculated",
"display": "Result with intervention alone (calculated)"
}
],
"text": "result with intervention with calculated value derived from the control group and effect estimate"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Result With Treatment (Calculated)</p></div>"
}
},
{
"title": "Effect Estimate",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-vs-comparator",
"display": "Result with intervention vs. comparator"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Effect Estimate</p></div>"
}
},
{
"title": "Certainty of Evidence",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "certainty-of-evidence",
"display": "Certainty of Evidence"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Certainty of Evidence</p></div>"
}
},
{
"title": "Assertion",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "assertion",
"display": "Assertion"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What this means</p></div>"
}
}
]
},
{
"title": "Summary of Findings",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "summary-of-findings",
"display": "Summary of Findings"
}
]
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"emptyReason": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code": "notstarted",
"display": "Not Started"
}
]
},
"section": [
{
"title": "All-cause mortality",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "summary-of-findings-entry-for-a-single-outcome",
"display": "Summary of findings entry for a single outcome"
}
]
},
"focus": {
"reference": "EvidenceVariable/236953",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313956",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: All-cause mortality"
},
"section": [
{
"title": "Outcome",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "outcome-measure",
"display": "Outcome Measure"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>All-cause mortality</p></div>"
},
"entry": [
{
"reference": "EvidenceVariable/236953",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313956",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: All-cause mortality"
}
]
},
{
"title": "Sample Size",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "sample-size",
"display": "Sample Size"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>2 studies, 1282 participants</p></div>"
},
"entry": [
{
"reference": "Evidence/236954",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Result Without Treatment",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-comparator-alone",
"display": "Result with comparator alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.24</p></div>"
},
"entry": [
{
"reference": "Evidence/236955",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Observed",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone",
"display": "Result with intervention alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.22</p></div>"
},
"entry": [
{
"reference": "Evidence/293980",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-intervention-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Derived",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone-calculated",
"display": "Result with intervention alone (calculated)"
}
],
"text": "result with intervention with calculated value derived from the control group and effect estimate"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>21.8%</p></div>"
},
"entry": [
{
"reference": "Evidence/236955",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference": "Evidence/236954",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Effect Estimate",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-vs-comparator",
"display": "Result with intervention vs. comparator"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -2.3% ( -4% to -0.4%); Odds Ratio 0.88 ( 0.79 to 0.98)</p></div>"
},
"entry": [
{
"reference": "Evidence/236954",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Certainty of Evidence",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "certainty-of-evidence",
"display": "Certainty of Evidence"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty</p></div>"
},
"entry": [
{
"reference": "Evidence/236954",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Assertion",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "assertion",
"display": "Assertion"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>SGLT2 inhibitors probably reduce the risk of all cause mortality compared with GLP-1 receptor agonists.</p></div>"
},
"entry": [
{
"reference": "Evidence/236954",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title": "Cardiovascular mortality",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "summary-of-findings-entry-for-a-single-outcome",
"display": "Summary of findings entry for a single outcome"
}
]
},
"focus": {
"reference": "EvidenceVariable/236956",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313957",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Cardiovascular mortality"
},
"section": [
{
"title": "Outcome",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "outcome-measure",
"display": "Outcome Measure"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Cardiovascular mortality</p></div>"
},
"entry": [
{
"reference": "EvidenceVariable/236956",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313957",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Cardiovascular mortality"
}
]
},
{
"title": "Sample Size",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "sample-size",
"display": "Sample Size"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>"
},
"entry": [
{
"reference": "Evidence/236957",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Result Without Treatment",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-comparator-alone",
"display": "Result with comparator alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.16</p></div>"
},
"entry": [
{
"reference": "Evidence/236958",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Observed",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone",
"display": "Result with intervention alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.15</p></div>"
},
"entry": [
{
"reference": "Evidence/293981",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-intervention-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Derived",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone-calculated",
"display": "Result with intervention alone (calculated)"
}
],
"text": "result with intervention with calculated value derived from the control group and effect estimate"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>15.2%</p></div>"
},
"entry": [
{
"reference": "Evidence/236958",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference": "Evidence/236957",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Effect Estimate",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-vs-comparator",
"display": "Result with intervention vs. comparator"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -0.5% ( -2.2% to 1.2%); Odds Ratio 0.96 ( 0.84 to 1.09)</p></div>"
},
"entry": [
{
"reference": "Evidence/236957",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Certainty of Evidence",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "certainty-of-evidence",
"display": "Certainty of Evidence"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty</p></div>"
},
"entry": [
{
"reference": "Evidence/236957",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Assertion",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "assertion",
"display": "Assertion"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.</p></div>"
},
"entry": [
{
"reference": "Evidence/236957",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title": "Nonfatal myocardial infarction",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "summary-of-findings-entry-for-a-single-outcome",
"display": "Summary of findings entry for a single outcome"
}
]
},
"focus": {
"reference": "EvidenceVariable/236959",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313958",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Nonfatal myocardial infarction"
},
"section": [
{
"title": "Outcome",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "outcome-measure",
"display": "Outcome Measure"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Nonfatal myocardial infarction</p></div>"
},
"entry": [
{
"reference": "EvidenceVariable/236959",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313958",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Nonfatal myocardial infarction"
}
]
},
{
"title": "Sample Size",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "sample-size",
"display": "Sample Size"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>"
},
"entry": [
{
"reference": "Evidence/236960",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Result Without Treatment",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-comparator-alone",
"display": "Result with comparator alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.18</p></div>"
},
"entry": [
{
"reference": "Evidence/236961",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Observed",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone",
"display": "Result with intervention alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.17</p></div>"
},
"entry": [
{
"reference": "Evidence/293982",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-intervention-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Derived",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone-calculated",
"display": "Result with intervention alone (calculated)"
}
],
"text": "result with intervention with calculated value derived from the control group and effect estimate"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>17%</p></div>"
},
"entry": [
{
"reference": "Evidence/236961",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference": "Evidence/236960",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Effect Estimate",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-vs-comparator",
"display": "Result with intervention vs. comparator"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -0.7% ( -2.4% to 1.1%); Odds Ratio 0.95 ( 0.84 to 1.08)</p></div>"
},
"entry": [
{
"reference": "Evidence/236960",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Certainty of Evidence",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "certainty-of-evidence",
"display": "Certainty of Evidence"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty</p></div>"
},
"entry": [
{
"reference": "Evidence/236960",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Assertion",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "assertion",
"display": "Assertion"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of nonfatal myocardial infarction.</p></div>"
},
"entry": [
{
"reference": "Evidence/236960",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title": "Nonfatal stroke",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "summary-of-findings-entry-for-a-single-outcome",
"display": "Summary of findings entry for a single outcome"
}
]
},
"focus": {
"reference": "EvidenceVariable/236962",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313959",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Nonfatal stroke"
},
"section": [
{
"title": "Outcome",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "outcome-measure",
"display": "Outcome Measure"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Nonfatal stroke</p></div>"
},
"entry": [
{
"reference": "EvidenceVariable/236962",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313959",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Nonfatal stroke"
}
]
},
{
"title": "Sample Size",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "sample-size",
"display": "Sample Size"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>2 studies, 1282 participants</p></div>"
},
"entry": [
{
"reference": "Evidence/236963",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Result Without Treatment",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-comparator-alone",
"display": "Result with comparator alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.17</p></div>"
},
"entry": [
{
"reference": "Evidence/236964",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Observed",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone",
"display": "Result with intervention alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.19</p></div>"
},
"entry": [
{
"reference": "Evidence/293983",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-intervention-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Derived",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone-calculated",
"display": "Result with intervention alone (calculated)"
}
],
"text": "result with intervention with calculated value derived from the control group and effect estimate"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>19.2%</p></div>"
},
"entry": [
{
"reference": "Evidence/236964",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference": "Evidence/236963",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Effect Estimate",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-vs-comparator",
"display": "Result with intervention vs. comparator"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 2.7% ( 0.4% to 5.3%); Odds Ratio 1.2 ( 1.03 to 1.41)</p></div>"
},
"entry": [
{
"reference": "Evidence/236963",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Certainty of Evidence",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "certainty-of-evidence",
"display": "Certainty of Evidence"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty</p></div>"
},
"entry": [
{
"reference": "Evidence/236963",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Assertion",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "assertion",
"display": "Assertion"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p> SGLT2 inhibitors probably increase the risk of nonfatal stroke compared with GLP-1 receptor agonists.</p></div>"
},
"entry": [
{
"reference": "Evidence/236963",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title": "End-stage kidney disease",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "summary-of-findings-entry-for-a-single-outcome",
"display": "Summary of findings entry for a single outcome"
}
]
},
"focus": {
"reference": "EvidenceVariable/236965",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313960",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: End-stage kidney disease"
},
"section": [
{
"title": "Outcome",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "outcome-measure",
"display": "Outcome Measure"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>End-stage kidney disease</p></div>"
},
"entry": [
{
"reference": "EvidenceVariable/236965",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313960",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: End-stage kidney disease"
}
]
},
{
"title": "Sample Size",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "sample-size",
"display": "Sample Size"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>"
},
"entry": [
{
"reference": "Evidence/236966",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Result Without Treatment",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-comparator-alone",
"display": "Result with comparator alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.12</p></div>"
},
"entry": [
{
"reference": "Evidence/236967",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Observed",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone",
"display": "Result with intervention alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.11</p></div>"
},
"entry": [
{
"reference": "Evidence/293984",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-intervention-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Derived",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone-calculated",
"display": "Result with intervention alone (calculated)"
}
],
"text": "result with intervention with calculated value derived from the control group and effect estimate"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>10.9%</p></div>"
},
"entry": [
{
"reference": "Evidence/236967",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference": "Evidence/236966",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Effect Estimate",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-vs-comparator",
"display": "Result with intervention vs. comparator"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -1% ( -3.4% to 2%); Odds Ratio 0.91 ( 0.69 to 1.2)</p></div>"
},
"entry": [
{
"reference": "Evidence/236966",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Certainty of Evidence",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "certainty-of-evidence",
"display": "Certainty of Evidence"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty</p></div>"
},
"entry": [
{
"reference": "Evidence/236966",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Assertion",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "assertion",
"display": "Assertion"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.</p></div>"
},
"entry": [
{
"reference": "Evidence/236966",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title": "Heart failure",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "summary-of-findings-entry-for-a-single-outcome",
"display": "Summary of findings entry for a single outcome"
}
]
},
"focus": {
"reference": "EvidenceVariable/236968",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313961",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Heart failure"
},
"section": [
{
"title": "Outcome",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "outcome-measure",
"display": "Outcome Measure"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Heart failure</p></div>"
},
"entry": [
{
"reference": "EvidenceVariable/236968",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313961",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Heart failure"
}
]
},
{
"title": "Sample Size",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "sample-size",
"display": "Sample Size"
}
]
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No sample size data found.]</p></div>"
},
"entry": [
{
"reference": "Evidence/236969",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Result Without Treatment",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-comparator-alone",
"display": "Result with comparator alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.22</p></div>"
},
"entry": [
{
"reference": "Evidence/236970",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Observed",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone",
"display": "Result with intervention alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.18</p></div>"
},
"entry": [
{
"reference": "Evidence/293985",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-intervention-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Derived",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone-calculated",
"display": "Result with intervention alone (calculated)"
}
],
"text": "result with intervention with calculated value derived from the control group and effect estimate"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>17.6%</p></div>"
},
"entry": [
{
"reference": "Evidence/236970",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference": "Evidence/236969",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Effect Estimate",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-vs-comparator",
"display": "Result with intervention vs. comparator"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -4.8% ( -6.6% to -2.7%); Odds Ratio 0.74 ( 0.65 to 0.85)</p></div>"
},
"entry": [
{
"reference": "Evidence/236969",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Certainty of Evidence",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "certainty-of-evidence",
"display": "Certainty of Evidence"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>High certainty</p></div>"
},
"entry": [
{
"reference": "Evidence/236969",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Assertion",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "assertion",
"display": "Assertion"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>SGLT2 inhibitors reduce the risk of heart failure compared with GLP-1 receptor agonists.</p></div>"
},
"entry": [
{
"reference": "Evidence/236969",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title": "Diabetic ketoacidosis",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "summary-of-findings-entry-for-a-single-outcome",
"display": "Summary of findings entry for a single outcome"
}
]
},
"focus": {
"reference": "EvidenceVariable/236971",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313962",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Diabetic ketoacidosis"
},
"section": [
{
"title": "Outcome",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "outcome-measure",
"display": "Outcome Measure"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Diabetic ketoacidosis</p></div>"
},
"entry": [
{
"reference": "EvidenceVariable/236971",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313962",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Diabetic ketoacidosis"
}
]
},
{
"title": "Sample Size",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "sample-size",
"display": "Sample Size"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>"
},
"entry": [
{
"reference": "Evidence/236972",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Result Without Treatment",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-comparator-alone",
"display": "Result with comparator alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0</p></div>"
},
"entry": [
{
"reference": "Evidence/236973",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Observed",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone",
"display": "Result with intervention alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0</p></div>"
},
"entry": [
{
"reference": "Evidence/293986",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-intervention-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Derived",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone-calculated",
"display": "Result with intervention alone (calculated)"
}
],
"text": "result with intervention with calculated value derived from the control group and effect estimate"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.2%</p></div>"
},
"entry": [
{
"reference": "Evidence/236973",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference": "Evidence/236972",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Effect Estimate",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-vs-comparator",
"display": "Result with intervention vs. comparator"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 0.1% ( 0% to 0.3%); Odds Ratio 1.71 ( 0.79 to 3.69)</p></div>"
},
"entry": [
{
"reference": "Evidence/236972",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Certainty of Evidence",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "certainty-of-evidence",
"display": "Certainty of Evidence"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>High certainty</p></div>"
},
"entry": [
{
"reference": "Evidence/236972",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Assertion",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "assertion",
"display": "Assertion"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of diabetic ketoacidosis.</p></div>"
},
"entry": [
{
"reference": "Evidence/236972",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title": "Serious hyperglycaemia",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "summary-of-findings-entry-for-a-single-outcome",
"display": "Summary of findings entry for a single outcome"
}
]
},
"focus": {
"reference": "EvidenceVariable/236974",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313963",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Serious hyperglycaemia"
},
"section": [
{
"title": "Outcome",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "outcome-measure",
"display": "Outcome Measure"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Serious hyperglycaemia</p></div>"
},
"entry": [
{
"reference": "EvidenceVariable/236974",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313963",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Serious hyperglycaemia"
}
]
},
{
"title": "Sample Size",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "sample-size",
"display": "Sample Size"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>"
},
"entry": [
{
"reference": "Evidence/236975",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Result Without Treatment",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-comparator-alone",
"display": "Result with comparator alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.01</p></div>"
},
"entry": [
{
"reference": "Evidence/236976",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Observed",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone",
"display": "Result with intervention alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.01</p></div>"
},
"entry": [
{
"reference": "Evidence/293987",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-intervention-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Derived",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone-calculated",
"display": "Result with intervention alone (calculated)"
}
],
"text": "result with intervention with calculated value derived from the control group and effect estimate"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1.5%</p></div>"
},
"entry": [
{
"reference": "Evidence/236976",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference": "Evidence/236975",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Effect Estimate",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-vs-comparator",
"display": "Result with intervention vs. comparator"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 0.5% ( -0.2% to 1.9%); Odds Ratio 1.48 ( 0.75 to 2.93)</p></div>"
},
"entry": [
{
"reference": "Evidence/236975",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Certainty of Evidence",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "certainty-of-evidence",
"display": "Certainty of Evidence"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>High certainty</p></div>"
},
"entry": [
{
"reference": "Evidence/236975",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Assertion",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "assertion",
"display": "Assertion"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of serious hyperglycaemia.</p></div>"
},
"entry": [
{
"reference": "Evidence/236975",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title": "Genital infection",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "summary-of-findings-entry-for-a-single-outcome",
"display": "Summary of findings entry for a single outcome"
}
]
},
"focus": {
"reference": "EvidenceVariable/236977",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313964",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Genital infection"
},
"section": [
{
"title": "Outcome",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "outcome-measure",
"display": "Outcome Measure"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Genital infection</p></div>"
},
"entry": [
{
"reference": "EvidenceVariable/236977",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313964",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Genital infection"
}
]
},
{
"title": "Sample Size",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "sample-size",
"display": "Sample Size"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>2 studies, 1282 participants</p></div>"
},
"entry": [
{
"reference": "Evidence/236978",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Result Without Treatment",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-comparator-alone",
"display": "Result with comparator alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.05</p></div>"
},
"entry": [
{
"reference": "Evidence/236979",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Observed",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone",
"display": "Result with intervention alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.21</p></div>"
},
"entry": [
{
"reference": "Evidence/293988",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-intervention-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Derived",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone-calculated",
"display": "Result with intervention alone (calculated)"
}
],
"text": "result with intervention with calculated value derived from the control group and effect estimate"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>20.8%</p></div>"
},
"entry": [
{
"reference": "Evidence/236979",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference": "Evidence/236978",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Effect Estimate",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-vs-comparator",
"display": "Result with intervention vs. comparator"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 15.8% ( 6.4% to 29.9%); Odds Ratio 5 ( 2.45 to 10.2)</p></div>"
},
"entry": [
{
"reference": "Evidence/236978",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Certainty of Evidence",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "certainty-of-evidence",
"display": "Certainty of Evidence"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>High certainty</p></div>"
},
"entry": [
{
"reference": "Evidence/236978",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Assertion",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "assertion",
"display": "Assertion"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>SGLT2 inhibitors increase the risk of genital infection compared with GLP-1 receptor agonists.</p></div>"
},
"entry": [
{
"reference": "Evidence/236978",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title": "Severe gastrointestinal events",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "summary-of-findings-entry-for-a-single-outcome",
"display": "Summary of findings entry for a single outcome"
}
]
},
"focus": {
"reference": "EvidenceVariable/236980",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313965",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Severe gastrointestinal events"
},
"section": [
{
"title": "Outcome",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "outcome-measure",
"display": "Outcome Measure"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Severe gastrointestinal events</p></div>"
},
"entry": [
{
"reference": "EvidenceVariable/236980",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313965",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Severe gastrointestinal events"
}
]
},
{
"title": "Sample Size",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "sample-size",
"display": "Sample Size"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>7 studies, 24638 participants</p></div>"
},
"entry": [
{
"reference": "Evidence/236981",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Result Without Treatment",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-comparator-alone",
"display": "Result with comparator alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.04</p></div>"
},
"entry": [
{
"reference": "Evidence/236982",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Observed",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone",
"display": "Result with intervention alone"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.1</p></div>"
},
"entry": [
{
"reference": "Evidence/293989",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-intervention-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Derived",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone-calculated",
"display": "Result with intervention alone (calculated)"
}
],
"text": "result with intervention with calculated value derived from the control group and effect estimate"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>10.2%</p></div>"
},
"entry": [
{
"reference": "Evidence/236982",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference": "Evidence/236981",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Effect Estimate",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-vs-comparator",
"display": "Result with intervention vs. comparator"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 5.8% ( 0.9% to 14.2%); Odds Ratio 2.46 ( 1.22 to 4.97)</p></div>"
},
"entry": [
{
"reference": "Evidence/236981",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Certainty of Evidence",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "certainty-of-evidence",
"display": "Certainty of Evidence"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Very low certainty</p></div>"
},
"entry": [
{
"reference": "Evidence/236981",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Assertion",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "assertion",
"display": "Assertion"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>GLP-1 receptor agonists may increase the risk of severe gastrointestinal events compared with SGLT2 inhibitors.</p></div>"
},
"entry": [
{
"reference": "Evidence/236981",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title": "Health-related quality of life",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "summary-of-findings-entry-for-a-single-outcome",
"display": "Summary of findings entry for a single outcome"
}
]
},
"focus": {
"reference": "EvidenceVariable/236983",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-109587",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Health-related quality of life"
},
"section": [
{
"title": "Outcome",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "outcome-measure",
"display": "Outcome Measure"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Health-related quality of life</p></div>"
},
"entry": [
{
"reference": "EvidenceVariable/236983",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-109587",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Health-related quality of life"
}
]
},
{
"title": "Sample Size",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "sample-size",
"display": "Sample Size"
}
]
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No sample size data found.]</p></div>"
},
"entry": [
{
"reference": "Evidence/236984",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Result Without Treatment",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-comparator-alone",
"display": "Result with comparator alone"
}
]
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Not a proportion.]</p></div>"
},
"entry": [
{
"reference": "Evidence/236985",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Observed",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone",
"display": "Result with intervention alone"
}
]
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Not a proportion.]</p></div>"
},
"entry": [
{
"reference": "Evidence/293990",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-intervention-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Derived",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone-calculated",
"display": "Result with intervention alone (calculated)"
}
],
"text": "result with intervention with calculated value derived from the control group and effect estimate"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Not a proportion.]</p></div>"
},
"entry": [
{
"reference": "Evidence/236985",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference": "Evidence/236984",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Effect Estimate",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-vs-comparator",
"display": "Result with intervention vs. comparator"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Standardized Mean Difference 0.01 ( -0.19 to 0.2)</p></div>"
},
"entry": [
{
"reference": "Evidence/236984",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Certainty of Evidence",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "certainty-of-evidence",
"display": "Certainty of Evidence"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Low certainty</p></div>"
},
"entry": [
{
"reference": "Evidence/236984",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Assertion",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "assertion",
"display": "Assertion"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There may be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on health-related quality of life.</p></div>"
},
"entry": [
{
"reference": "Evidence/236984",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title": "Body weight",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "summary-of-findings-entry-for-a-single-outcome",
"display": "Summary of findings entry for a single outcome"
}
]
},
"focus": {
"reference": "EvidenceVariable/236986",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-109588",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Body weight"
},
"section": [
{
"title": "Outcome",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "outcome-measure",
"display": "Outcome Measure"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Body weight</p></div>"
},
"entry": [
{
"reference": "EvidenceVariable/236986",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-109588",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Body weight"
}
]
},
{
"title": "Sample Size",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "sample-size",
"display": "Sample Size"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>2 studies, 1139 participants</p></div>"
},
"entry": [
{
"reference": "Evidence/236987",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Result Without Treatment",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-comparator-alone",
"display": "Result with comparator alone"
}
]
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Not a proportion.]</p></div>"
},
"entry": [
{
"reference": "Evidence/236988",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Observed",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone",
"display": "Result with intervention alone"
}
]
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Not a proportion.]</p></div>"
},
"entry": [
{
"reference": "Evidence/293991",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-intervention-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title": "Result With Treatment--Derived",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-alone-calculated",
"display": "Result with intervention alone (calculated)"
}
],
"text": "result with intervention with calculated value derived from the control group and effect estimate"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Not a proportion.]</p></div>"
},
"entry": [
{
"reference": "Evidence/236988",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparator-only-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference": "Evidence/236987",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Effect Estimate",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "result-with-intervention-vs-comparator",
"display": "Result with intervention vs. comparator"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Mean Difference -0.47 Kg ( -0.09 Kg to -0.85 Kg)</p></div>"
},
"entry": [
{
"reference": "Evidence/236987",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Certainty of Evidence",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "certainty-of-evidence",
"display": "Certainty of Evidence"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty</p></div>"
},
"entry": [
{
"reference": "Evidence/236987",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title": "Assertion",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "assertion",
"display": "Assertion"
}
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>SGLT2 inhibitors probably reduce body weight compared with GLP-1 receptor agonists.</p></div>"
},
"entry": [
{
"reference": "Evidence/236987",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
}
]
},
{
"title": "Groups",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "groups",
"display": "Groups"
}
]
},
"section": [
{
"title": "Total Group",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "population",
"display": "Population"
}
]
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"emptyReason": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code": "notstarted",
"display": "Not Started"
}
]
}
},
{
"title": "Intervention Group",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "intervention-group",
"display": "Intervention Group"
}
]
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"emptyReason": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code": "notstarted",
"display": "Not Started"
}
]
}
},
{
"title": "Comparator Group",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "comparator-group",
"display": "Comparator Group"
}
]
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"emptyReason": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code": "notstarted",
"display": "Not Started"
}
]
}
},
{
"title": "Group Assignment",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "GroupAssignment",
"display": "GroupAssignment"
}
]
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"emptyReason": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code": "notstarted",
"display": "Not Started"
}
]
}
}
]
},
{
"title": "Variables (Measures)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "variables",
"display": "Variables"
}
]
},
"text": {
"status": "empty",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"entry": [
{
"reference": "EvidenceVariable/236953",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313956",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: All-cause mortality"
},
{
"reference": "EvidenceVariable/236956",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313957",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Cardiovascular mortality"
},
{
"reference": "EvidenceVariable/236959",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313958",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Nonfatal myocardial infarction"
},
{
"reference": "EvidenceVariable/236962",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313959",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Nonfatal stroke"
},
{
"reference": "EvidenceVariable/236965",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313960",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: End-stage kidney disease"
},
{
"reference": "EvidenceVariable/236968",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313961",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Heart failure"
},
{
"reference": "EvidenceVariable/236971",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313962",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Diabetic ketoacidosis"
},
{
"reference": "EvidenceVariable/236974",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313963",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Serious hyperglycaemia"
},
{
"reference": "EvidenceVariable/236977",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313964",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Genital infection"
},
{
"reference": "EvidenceVariable/236980",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313965",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Severe gastrointestinal events"
},
{
"reference": "EvidenceVariable/236983",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-109587",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Health-related quality of life"
},
{
"reference": "EvidenceVariable/236986",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-109588",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "OutcomeDefinition: Body weight"
}
]
}
]
}